We look forward to deepening our collaboration with IBA and are confident that this joint approach has the potential to make non-uranium Mo-99 the leading worldwide source of Tc-99m.”
We are proud to lead the field of nuclear medicine as the only commercialized producer of Mo-99 in the United States, having provided more than two years of stable U.S. Based on their commercial expertise and tailored approach, we believe IBA complements NorthStar’s global vision of delivering innovative solutions that can address critical patient healthcare needs related to medical diagnosis. “NorthStar is delighted to expand its collaboration with IBA, as we view them to be an ideal partner to grow the use of non-uranium based Mo-99 to support a sustainable and innovative future for nuclear medicine. “Every year approximately 30 million patients benefit from diagnostic imaging studies using Tc-99m,” said Stephen Merrick, President and Chief Executive Officer of NorthStar, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications. Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world.
Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99). The collaboration enables companies outside of the United States to access the Tc-99m Generation Systems (TCM Generation Systems) that utilize NorthStar’s proprietary non-uranium based Mo-99 produced using IBA’s accelerators and beamlines. NorthStar Medical Radioisotopes and IBA (Ion Beam Applications S.A., EURONEXT) recently announced a collaboration to increase global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope.